Cardiac Catheterization. What the Procedure Is and What It Shows.

Cardiac catheterization is the procedure cardiologists order when the anatomy of the coronary arteries needs to be known with certainty: when a stress test is positive, when symptoms are consistent with unstable angina, or when a patient has had a heart attack and revascularization is on the table. No non-invasive test provides the same level of anatomical detail. 4 / Promising

The Mechanism

The coronary arteries are the two vessels that originate at the aortic root, just above the aortic valve, and supply blood to the heart muscle itself. The left main coronary artery divides into the left anterior descending (LAD) and left circumflex arteries, supplying most of the left ventricle. The right coronary artery (RCA) supplies the right ventricle and, in most patients, the inferior wall of the left ventricle and the sinoatrial and atrioventricular nodes.

Atherosclerotic plaque narrows these vessels over decades. The physiological consequence depends on the degree of stenosis. Moderate stenoses (40 to 60 percent of lumen diameter) may be hemodynamically insignificant at rest but produce ischemia with exercise as oxygen demand increases and the restricted lumen cannot deliver adequate blood flow. Severe stenoses (70 percent or greater) typically produce symptoms or ischemic changes on testing. Total occlusions produce infarction when they occur acutely, or can be chronically occluded with collateral vessel compensation if the process has been gradual.

Cardiac catheterization, formally called coronary angiography, uses the principle of arterial access to deliver contrast dye directly to the coronary ostia (the openings of the coronary arteries at the aortic root) under real-time X-ray imaging (fluoroscopy). Contrast dye is radiopaque and outlines the arterial lumen when injected. Where the artery is normal, the contrast column is uniform. Where plaque has narrowed the lumen, the contrast column is reduced: this appears as a filling defect or a narrowing of the outlined vessel. Multiple angiographic projections (different angles of the X-ray beam) are obtained to characterize each lesion from multiple perspectives, since a stenosis that appears mild in one projection may appear severe in another.

The procedure takes place in a cardiac catheterization laboratory equipped with a fluoroscopic imaging system, monitoring equipment, and emergency resuscitation capability. The patient is awake under conscious sedation (typically midazolam and fentanyl), lying flat on the catheterization table. The procedure is performed under sterile technique.

Access is established through an artery, most commonly the radial artery at the wrist or the femoral artery in the groin. After local anesthesia, a small needle puncture is made and a wire-guided introducer sheath is placed in the artery. Through this sheath, a series of diagnostic catheters are advanced under fluoroscopic guidance through the aorta to the coronary ostia. Each major vessel is selectively injected and imaged in multiple projections. The full diagnostic study takes 30 to 45 minutes in experienced hands.

What the Evidence Shows

The shift from femoral (groin) to radial (wrist) access has been one of the most significant procedural quality improvements in interventional cardiology over the past two decades. The evidence base is substantial. 5 / Solid

The MATRIX trial, published in The Lancet in 2015, enrolled 8,404 patients with acute coronary syndrome undergoing catheterization and randomized them to radial versus femoral access. Radial access reduced the composite of death, MI, stroke, and major bleeding at 30 days. All-cause mortality was lower in the radial group (1.6 vs. 2.2 percent, p=0.045). The benefit was driven primarily by fewer access site bleeding complications.

The RIVAL trial, published in The Lancet in 2011, enrolled 7,021 patients with ACS and found that radial access reduced access site complications with equivalent procedure success rates. In the subgroup with ST-elevation MI, radial access reduced mortality by 30 percent.

The mechanism of benefit from radial access is primarily reduction in access site bleeding. The femoral artery, accessed in the groin, is a large vessel in proximity to the retroperitoneum. Femoral access site bleeding can be extensive and difficult to detect early. The radial artery is superficial, easily compressible, and surrounded by a small tissue compartment. Major bleeding from radial access is rare. Because bleeding after ACS catheterization is itself independently associated with increased mortality (a relationship established in the ACUITY and REPLACE-2 trials), reducing access site bleeding translates directly to improved survival.

Radial access also allows patients to sit up immediately after the procedure. With femoral access, patients must remain flat for several hours while hemostasis is achieved at the groin site, increasing time to ambulation, length of stay, and patient discomfort. Most high-volume catheterization centers in the United States now perform the majority of elective and acute cases via radial access, with femoral reserved for cases where radial access is anatomically difficult or unsuitable.

Fractional flow reserve (FFR) represents a second major evidence-based advance in how catheterization findings are used. Coronary angiography provides anatomical information: the degree to which a stenosis narrows the vessel lumen. It does not tell you directly whether that stenosis is causing ischemia. A 60 percent stenosis on angiography may or may not be hemodynamically significant.

FFR uses a pressure sensor mounted on a guidewire placed across the stenosis. Under pharmacological vasodilation (typically adenosine, which maximizes coronary blood flow), the pressure drop across the stenosis is measured. FFR is calculated as the ratio of distal-to-proximal coronary pressure. An FFR at or below 0.80 indicates that the stenosis is producing sufficient flow limitation to cause ischemia; stenting it reduces cardiovascular events. An FFR above 0.80 indicates the stenosis is not hemodynamically significant, and stenting it does not reduce events and may increase risk.

The DEFER trial established that deferring stenting of FFR-negative lesions was safe, with equivalent five-year outcomes to lesions that were not stented based on FFR. The FAME trial, published in the NEJM in 2009 and enrolling 1,005 patients with multivessel coronary disease, found that FFR-guided PCI reduced the composite of death, MI, and repeat revascularization by 28 percent compared to angiography-guided PCI. The FAME-2 trial subsequently confirmed that FFR-positive lesions treated with PCI had lower rates of urgent revascularization than medical therapy alone.

The practical consequence: FFR guidance reduces unnecessary stent placement, reduces procedure time and contrast exposure, and produces equivalent or better cardiovascular outcomes by directing intervention only to lesions that are actually causing ischemia.

What to Do This Week

1. If a cardiac catheterization has been recommended and your clinical situation is not an emergency, ask specifically whether your operator performs radial access routinely and what percentage of their cases use the radial approach. Most high-volume interventionalists exceed 80 to 90 percent radial access rates. Radial access is the preferred approach per current ACC/AHA guidelines for both elective and acute indications.

2. Ask whether FFR will be used if a stenosis of unclear significance is found. The ACC and ESC guidelines recommend FFR for intermediate stenoses (40 to 70 percent on angiography) where the hemodynamic significance is uncertain. If you have a known history of multivessel coronary disease, ask whether FFR-guided decision-making is part of your center’s standard protocol.

3. Before the procedure, discuss with your cardiologist the two main outcomes so you are prepared for either: the catheterization shows no obstructive coronary disease (reassuring and common, particularly in younger patients evaluated for atypical chest pain), or the catheterization identifies a significant lesion requiring management. If a lesion is found, the three options are ad hoc PCI at the same sitting, staged PCI as a separate procedure, or referral for surgical bypass (CABG) if the anatomy warrants it. Understanding these paths before the procedure prevents surprise decision-making in the catheterization laboratory.

4. Ask about your center’s major complication rate for diagnostic angiography. In experienced, high-volume centers, the risk of major adverse events (stroke, MI, or death) from diagnostic coronary angiography is below 0.1 to 0.5 percent. The risk from radial access site complications (significant bleeding or vessel injury) is lower than from femoral access. Knowing the risk framing helps you make an informed decision about the risk-benefit calculation, particularly for elective diagnostic studies.

5. If you receive a report after catheterization that lists specific stenosis percentages, ask specifically: “Were any of these lesions functionally assessed with FFR or instantaneous wave-free ratio?” A 55 percent stenosis that was not functionally assessed provides anatomical but not physiological information. For management decisions in stable coronary disease, functional assessment of intermediate lesions is the evidence-based standard.

Intravascular Imaging: When the Angiogram Is Not the Full Picture

Coronary angiography images the lumen — the blood-filled channel inside the vessel — by tracking where contrast dye fills and where it does not. What it cannot directly visualize is the vessel wall itself, which is where plaque deposits, remodels, and sometimes ruptures. Two catheter-based imaging modalities acquire cross-sectional views of the vessel wall during the same procedure, adding information that changes what decisions are possible.

Intravascular ultrasound (IVUS) mounts a miniature ultrasound transducer on a catheter advanced into the coronary artery. As the catheter is withdrawn, it produces cross-sectional images of the vessel wall at approximately 100 to 200 micron resolution. IVUS can quantify total plaque burden including atherosclerosis that does not narrow the lumen significantly on angiography, measure the minimal lumen area within a stenosis, assess plaque composition between calcified and non-calcified segments, and verify that a deployed stent has been appropriately expanded and is in full contact with the vessel wall.

Optical coherence tomography (OCT) uses infrared light rather than ultrasound and achieves approximately ten times the resolution of IVUS — around 10 to 20 microns — at the cost of shallower penetration depth. OCT can identify thin-cap fibroatheroma, the vulnerable plaque morphology where a thin fibrous cap overlies a lipid-rich necrotic core. A cap thickness below 65 microns on OCT is considered the threshold for vulnerability. OCT can also distinguish plaque erosion from plaque rupture as the mechanism of an acute presentation, information that can change acute management strategy.

The ILUMIEN III trial, published in the New England Journal of Medicine in 2023 by Ali and colleagues, randomized 2,487 patients undergoing coronary intervention to OCT guidance, IVUS guidance, or angiography guidance alone. The primary endpoint was minimum stent expansion — a measure of deployment quality that predicts restenosis and stent thrombosis risk. OCT-guided PCI was non-inferior to IVUS-guided PCI, and both imaging-guided approaches were superior to angiography alone for achieving optimal stent expansion. Under-expansion is the primary procedural cause of stent-related long-term complications. 5 / Solid

For a patient undergoing coronary intervention, whether intravascular imaging was or will be used to guide stent deployment is a legitimate clinical question, particularly in complex anatomy, bifurcation lesions, or heavily calcified stenoses where angiographic guidance alone is known to underperform.

Before and After the Procedure

Preparation for cardiac catheterization is straightforward. Patients are asked to fast for several hours before the procedure. Blood thinners may be held or continued depending on the indication (ACS patients typically continue antiplatelet therapy; elective patients are managed case by case). Metformin is held for 48 hours after contrast exposure to reduce the rare risk of contrast-associated nephropathy in patients with reduced kidney function.

Intravenous access is established before the procedure. Blood pressure, heart rate, and oxygen saturation are monitored continuously. After the procedure, the sheath is removed and hemostasis is achieved: for radial access, a compression wrist band is applied and removed over 2 to 4 hours; for femoral access, manual compression or a closure device is used and the patient remains flat for 2 to 6 hours. Radial access patients typically ambulate within one hour of sheath removal.

Contrast dye use requires attention to kidney function. Contrast-induced nephropathy, an acute decline in kidney function following iodinated contrast, occurs most often in patients with pre-existing kidney disease or diabetes and inadequate hydration. Pre-procedure intravenous hydration reduces this risk. In patients with significantly reduced kidney function (eGFR below 30 mL/min/1.73m2), the risk-benefit ratio requires explicit discussion. For patients with acute STEMI requiring emergency catheterization, the benefit of coronary reperfusion substantially outweighs the contrast risk in almost all circumstances.

After the procedure, most patients are monitored for 2 to 4 hours before discharge. A same-day discharge protocol following uncomplicated diagnostic angiography via radial access is now standard at most high-volume centers. Patients are asked to avoid heavy lifting and strenuous activity for 24 to 48 hours and to monitor the access site for bleeding or swelling.

The diagnostic information from coronary angiography is high-fidelity anatomical data that no other currently available test replicates. CT coronary angiography has become a high-quality non-invasive alternative for ruling out obstructive coronary disease in low-to-intermediate risk patients with stable symptoms; its spatial resolution and ability to characterize non-obstructive plaque burden have improved substantially. Invasive coronary angiography remains the reference standard when anatomy needs to be characterized precisely enough to guide revascularization decisions, when functional assessment with FFR is planned, or when the clinical situation demands both diagnosis and treatment in the same setting.